BCR and neoplasm: The effect of ZT55 on tumor cell proliferation was studied in 11 human cell lines of both hematologic and solid tumor origin, including HEL cells (harboring the JAK2V617F mutation), and TF-1 cells (carrying wild-type JAK2 but BCR-ABL-transformed).